ArticleInternational journal of women's health2026
Causal Effects of Circulating Inflammatory Proteins on Postmenopausal Atrophic Vaginitis in European Populations: A Mendelian Randomization Study with Transcriptomic Validation.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmenopausal atrophic vaginitis (PAV) is a prevalent and undertreated condition driven primarily by estrogen deficiency. Whether circulating inflammatory proteins causally contribute to PAV pathogenesis remains unknown. Methods: Genetic instruments for 91 inflammatory proteins were derived from large-scale proteogenomic GWAS of European ancestry individuals. PAV outcome data were obtained from the FinnGen Consortium Release 12. Primary causal estimates were obtained using the inverse-variance weighted (IVW) method, complemented by MR-Egger, weighted median, and weighted mode analyses. Candidate proteins were defined by IVW p < 0.05 and directional consistency across all four methods. Sensitivity analyses included the MR-Egger intercept test, Cochran's Q test, leave-one-out analysis, funnel plot assessment, and reverse MR. Transcriptomic validation was performed using the publicly available vaginal tissue dataset GSE26761. Results: Six inflammatory proteins met the candidate criteria: CCL19 (OR: 1.063, 95% CI: 1.003-1.126) and IL12B (OR: 1.050, 95% CI: 1.002-1.100) were associated with increased PAV risk, while CXCL5 (OR: 0.935, 95% CI: 0.874-0.999), TNFRSF9 (OR: 0.930, 95% CI: 0.869-0.996), IL10RA (OR: 0.906, 95% CI: 0.831-0.988), and TGFA (OR: 0.880, 95% CI: 0.790-0.981) were inversely associated with PAV risk. Sensitivity analyses revealed no significant pleiotropy or heterogeneity. Transcriptomic analysis confirmed significantly lower TGFA expression in atrophic compared to control vaginal tissue ( Conclusion: This study provides genetic evidence that circulating inflammatory proteins causally influence PAV risk through distinct immune pathways. TGFA emerges as the most robustly supported candidate, with convergent MR and transcriptomic evidence suggesting a role in vaginal epithelial maintenance. These findings highlight inflammation as a potential contributor to PAV pathogenesis and nominate candidate targets for future mechanistic and therapeutic investigation. Given that multiple inflammatory proteins were tested, these findings should be interpreted cautiously and warrant further validation in independent cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.